-
公开(公告)号：EP1890721B1
公开(公告)日：2010-09-22
申请号：EP06733813.7
申请日：2006-01-25
CPC分类号： A61K9/0019 , A61K38/1808 , A61K38/1825 , A61K38/1858 , A61K38/1866 , A61K38/2006 , A61K38/2093 , A61K38/212 , A61K38/2285 , A61K38/2292 , A61K38/30 , A61K2300/00
摘要： Pharmaceutical polypeptide compositions promote the survival of cardiac cells, recruit cardiac cells to the cardiac area, stimulate the differentiation of cardiac cells, stimulate the proliferation of cardiac cells, and promote the activity of cardiac cells, thereby treating cardiac conditions. Methods of providing these compositions to the cardiac area include catheterization and direct injection. In preferred embodiements, the compositions comprise one of more of the following growth factors: EGF, bFGF, cardiotrophin-1, thrombin, PDGF-BB, amphiregulin, epiregulin, HB-EGF, TGFalpha, betacellulin, heregulin alpha, NRG-1-betal-HRG-betal, FGF 9.
-
公开(公告)号：EP1778842B8
公开(公告)日：2012-03-21
申请号：EP05791762.7
申请日：2005-07-21
发明人： BEHRENS, Dirk , BOSCH, Elizabeth , DOBERSTEIN, Steven , HALENBECK, Robert, Forgan , HESTIR, Kevin , HUANG, Min, Mei , LEE, Ernestine , LIN, Haishan , LINNEMANN, Thomas Five Prime Therapeutics, Inc. , MARSHALL, Shannon , WONG, Justin, G., P. , WU, Ge , ZHOU, Aileen , LEO, Cindy , WILLIAMS, Lewis, T.
IPC分类号： C07K14/53
CPC分类号： C07K16/243 , A61K38/00 , C07K14/53
-
3.发明授权
公开(公告)号：EP1910542B1
公开(公告)日：2009-12-02
申请号：EP06800260.9
申请日：2006-07-24
发明人： WILLIAMS, Lewis, T. , BOSCH, Elizabeth , DOBERSTEIN, Stephen , HESTIR, Kevin , HOLLENBAUGH, Diane , LEE, Ernestine , QIN, Minmin , SADRA, Ali , WONG, Justin , WU, Ge , ZHANG, Hongbing
CPC分类号： C07K14/71 , A61K45/06 , C07K14/765 , C07K16/2863 , C07K17/08 , C07K2319/30 , C07K2319/32
摘要： The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
-
公开(公告)号：EP1778842A2
公开(公告)日：2007-05-02
申请号：EP05791762.7
申请日：2005-07-21
发明人： BEHRENS, Dirk , BOSCH, Elizabeth , DOBERTEIN, Steven , HALENBECK, Robert, Forgan , HESTIR, Kevin , HUANG, Min, Mei , LEE, Ernestine , LIN, Haishan , LINNEMANN, Thomas , MARSHALL, Shannon , WONG, Justin, G., P. , WU, Ge , ZHOU, Aileen , LEO, Cindy , WILLIAMS, Lewis, T.
IPC分类号： C12N15/27
CPC分类号： C07K16/243 , A61K38/00 , C07K14/53
摘要： Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.
-
公开(公告)号：EP1778842B1
公开(公告)日：2012-01-11
申请号：EP05791762.7
申请日：2005-07-21
发明人： BEHRENS, Dirk , BOSCH, Elizabeth , DOBERSTEIN, Steven , HALENBECK, Robert, Forgan , HESTIR, Kevin , HUANG, Min, Mei , LEE, Ernestine , LIN, Haishan , LINNEMANN, Thomas Five Prime Therapeutics, Inc. , MARSHALL, Shannon , WONG, Justin, G., P. , WU, Ge , ZHOU, Aileen , LEO, Cindy , WILLIAMS, Lewis, T.
IPC分类号： C07K14/53
CPC分类号： C07K16/243 , A61K38/00 , C07K14/53
摘要： Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.
-
6.发明公开
公开(公告)号：EP1910542A2
公开(公告)日：2008-04-16
申请号：EP06800260.9
申请日：2006-07-24
发明人： WILLIAMS, Lewis, T. , BOSCH, Elizabeth , DOBERSTEIN, Stephen , HESTIR, Kevin , HOLLENBAUGH, Diane , LEE, Ernestine , QIN, Minmin , SADRA, Ali , WONG, Justin , WU, Ge , ZHANG, Hongbing
CPC分类号： C07K14/71 , A61K45/06 , C07K14/765 , C07K16/2863 , C07K17/08 , C07K2319/30 , C07K2319/32
摘要： The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
-
7.发明公开FIBROBLAST GROWTH FACTOR RECEPTORS 1, 2, 3, AND 4 AS TARGETS FOR THERAPEUTIC INTERVENTION 审中-公开成纤维细胞生长因子受体1，2，3和4作为用于治疗性干预的靶标
公开(公告)号：EP1697420A2
公开(公告)日：2006-09-06
申请号：EP04814358.0
申请日：2004-12-17
发明人： ZENG, Changjiang , HESTIR, Kevin , PIERCE, Kristen , WILLIAMS, Lewis, T. , BOSCH, Elizabeth , MASUOKA, Lorianne , WONG, Justin, G., P. , WANG, Yan , CHU, Keting , LEE, Ernestine
CPC分类号： C07K16/2863 , C07K14/71 , G01N33/574 , G01N33/74 , G01N2333/50 , G01N2800/04 , G01N2800/065 , G01N2800/085 , G01N2800/102 , G01N2800/104 , G01N2800/105 , G01N2800/324
摘要： Isolated fibroblast growth factor receptor 1 (“FGFR1”), fibroblast growth factor receptor 2 (“FGFR2”), fibroblast growth factor receptor 3 (“FGFR3”), and fibroblast growth receptor 4 (“FGFR4”) polypeptides and polynucleotides encoding the FGFR1-4 polypeptides, respectively, are provided. Additionally, antibodies, directed to the FGFR1-4 polypeptides and polynucleotides, inclusive of all polymorphic forms and variants thereof, are described. These antibodies either specifically activate the polypeptide or specifically interfere with the activity of the polypeptide. Further provided are methods of treating diseases, such as proliferative diseases, inflammatory diseases, and metabolic disorders, and kits and compositions employing the disclosed compositions. Specifically disclosed is a method of treating tumors in a subject where an antagonist of FGFR1, FGFR2, FGFR3, and/or FGFR4 is administered to the subject.
-
8.发明公开METHODS OF AND COMPOSITIONS FOR STIMULATION OF GLUCOSE UPTAKE INTO MUSCLE CELLS AND TREATMENT OF DISEASES 审中-公开方法和组合物肌肉刺激的葡萄糖摄取和治疗疾病的
公开(公告)号：EP1890722A2
公开(公告)日：2008-02-27
申请号：EP06760525.3
申请日：2006-05-30
发明人： LIN, Junyu , KOTHAKOTA, Srinivas , WU, Ge , DOBERSTEIN, Stephen , BRENNAN, Thomas , MASUOKA, Lorianne , QIN, Minmin , MARSHALL, Shannon , WANG, Yan , HOLLENBAUGH, Diane , WILLIAMS, Lewis, T.
IPC分类号： A61K38/20
CPC分类号： A61K38/1883 , A61K31/155 , A61K31/18 , A61K31/195 , A61K31/197 , A61K38/1808 , A61K38/26 , A61K38/28 , A61K45/06 , A61K47/60 , A61K2300/00
摘要： The present invention relates to therapeutic uses of ErbB ligands, including betacellulin. The therapeutic uses include methods of using ErbB ligand family compounds alone, or in conjunction with other agents, for reducing blood glucose levels, treating Type I and Type II diabetes, obesity, muscle wasting diseases, and cardiotoxicity.
-
公开(公告)号：EP1890721A2
公开(公告)日：2008-02-27
申请号：EP06733813.7
申请日：2006-01-25
CPC分类号： A61K9/0019 , A61K38/1808 , A61K38/1825 , A61K38/1858 , A61K38/1866 , A61K38/2006 , A61K38/2093 , A61K38/212 , A61K38/2285 , A61K38/2292 , A61K38/30 , A61K2300/00
摘要： Pharmaceutical polypeptide compositions promote the survival of cardiac cells, recruit cardiac cells to the cardiac area, stimulate the differentiation of cardiac cells, stimulate the proliferation of cardiac cells, and promote the activity of cardiac cells, thereby treating cardiac conditions. Methods of providing these compositions to the cardiac area include catheterization and direct injection. In preferred embodiements, the compositions comprise one of more of the following growth factors: EGF, bFGF, cardiotrophin-1, thrombin, PDGF-BB, amphiregulin, epiregulin, HB-EGF, TGFalpha, betacellulin, heregulin alpha, NRG-1-betal-HRG-betal, FGF 9.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.025 秒)
